What Happened
- BioAsia 2026, the 23rd edition of Asia's premier life sciences summit, was held on February 17-18, 2026 at HITEX Exhibition Centre, Hyderabad, under the theme "TechBio Unleashed: AI, Automation & the Biology Revolution."
- India's capacity to scale next-generation biologics — including vaccines, RNA platforms, cell and gene therapies — took centre stage at the conference.
- Industry leaders highlighted India's ability to combine large-scale manufacturing infrastructure, skilled scientific talent, supportive regulatory frameworks, and growing international collaboration to position itself as a global hub.
- A dedicated panel discussed "Next-Gen Biologics & Advanced Modalities: From Discovery to Clinical Proof & CMC at Scale," emphasising Chemistry, Manufacturing, and Controls (CMC) capability as a differentiator.
- Telangana's Rising Vision 2047 roadmap for AI-enabled R&D, advanced modalities, and next-generation biomanufacturing was also presented, underlining the state's strategic ambitions in life sciences.
Static Topic Bridges
Biologics and Biosimilars: India's Emerging Role
Biologics are medicines derived from living organisms — including proteins, monoclonal antibodies, vaccines, and gene therapies — as distinct from chemically synthesised small-molecule drugs. Biosimilars are near-identical copies of approved reference biologics whose patents have expired. India ranks first globally in the number of biosimilar approvals (98 approvals as of recent data), and has progressively built capability in complex biologics including trastuzumab, rituximab, and adalimumab (monoclonal antibodies for oncology and immunology). Next-generation biologics extend this to RNA platforms (mRNA vaccines), cell therapy (CAR-T), and gene therapy.
- CDSCO (Central Drugs Standard Control Organisation) regulates biologics in India under the Drugs and Cosmetics Act
- India's biosimilar guidelines were formally issued in 2012 and revised in 2016 (and updated via CDSCO draft guidelines 2024) to align with EMA/FDA standards
- 44 biosimilar approvals between 2011-2015; over 25 more between 2016-2020
- India's pharma sector is the world's 3rd largest by volume and 14th by value
- Key clusters: Hyderabad (Genome Valley), Pune, Ahmedabad for biologics manufacturing
Connection to this news: BioAsia 2026 specifically called out India's ability to scale next-gen biologics beyond traditional biosimilars into RNA platforms and cell/gene therapies — the next frontier where regulatory and manufacturing readiness will determine global market access.
India's Pharma Sector and Global Manufacturing Hub Strategy
India's pharmaceutical industry generates approximately $50 billion in annual output, with exports exceeding $25 billion. The "Pharmacy of the World" designation reflects India's dominance in generic drugs supply to over 200 countries. The Production Linked Incentive (PLI) scheme for pharmaceuticals (approved 2020, ₹15,000 crore outlay) specifically incentivises high-value segments including biopharmaceuticals, complex generics, and active pharmaceutical ingredients (APIs) to reduce import dependence. Hyderabad's Genome Valley hosts over 200 life sciences companies including Dr. Reddy's, Bharat Biotech, and Biological E.
- PLI for Pharma: ₹15,000 crore for 2020-2028, covering biologics and complex APIs
- India supplies ~60% of global vaccine demand and ~20% of generic medicines
- Biosimilar market in India expected to grow significantly given patent cliff on large-molecule drugs globally through 2030
- BioAsia's Telangana Rising Vision 2047 signals state-level policy commitment to biomanufacturing scale-up
Connection to this news: The BioAsia discussions on CMC scale-up (Chemistry, Manufacturing, Controls) are directly linked to India's PLI strategy — building end-to-end domestic capability from discovery to commercial-scale manufacturing, not just contract manufacturing for multinationals.
AI-Biology Convergence: TechBio
TechBio refers to the convergence of artificial intelligence, automation, and computational methods with biological research and drug development. AI applications in biologics include protein structure prediction (AlphaFold), AI-guided clinical trial design, automated bioreactor optimisation, and predictive modelling for immunogenicity. BioAsia 2026's theme "TechBio Unleashed" reflects the global industry shift toward AI-native drug discovery. Drug development timelines have reportedly been compressed from typical 10-15 years to 3 years in some AI-assisted pathways, and R&D costs cut by up to 5%.
- AlphaFold (DeepMind) has predicted structures of over 200 million proteins — revolutionising biologics target identification
- AI-based drug discovery startups in India: Aganitha, Nference, and others in Hyderabad/Bengaluru ecosystems
- IndiaAI Mission (Rs 10,372 crore, approved March 2024) includes compute access for academic and pharma research
- CDSCO has yet to issue comprehensive AI-in-drug-development guidelines; global regulatory agencies (FDA, EMA) have begun issuing guidance
Connection to this news: BioAsia 2026's focus on AI and automation in biologics directly links India's pharma strengths with the emerging AI-for-science agenda, placing the sector at the intersection of two of India's strategic priorities.
Key Facts & Data
- BioAsia 2026: 23rd edition, February 17-18, 2026, HITEX Centre, Hyderabad; ~4,000 delegates (record attendance)
- Theme: "TechBio Unleashed: AI, Automation & the Biology Revolution"
- India biosimilar approvals: 98 (highest globally by number)
- India pharma exports: ~$25 billion/year; 3rd largest by volume globally
- PLI for Pharmaceuticals: ₹15,000 crore outlay (2020-2028)
- Drug development compression with AI: from ~10-15 years to potentially 3 years
- R&D cost reduction reported with AI tools: up to 5%
- Telangana Rising Vision 2047: AI-enabled biomanufacturing roadmap